Payment overview · 2025
General Payments
$495.55
4 reported records · 3 companies
Healthcare provider profile · identity verified
Brian Whyms, DO
Allopathic & Osteopathic Physicians|Internal Medicine · DES MOINES, IA · NPI 1821440066
Verified facts
What the public records show
CMS Open Payments records show Brian Whyms, DO received $495.55 in general payments during 2025 across 4 reported records.
Neurocrine BioSciences, Inc. accounted for 51.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nuplazid.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Nuplazid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $256.90 | 51.8% | 2 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$146.38 | 29.5% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $92.27 | 18.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $495.55 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $256.90 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $92.27 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 711 | 65 |
| Atorvastatin Calcium | Atorvastatin Calcium | 666 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 594 | 96 |
| Furosemide | Furosemide | 475 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 450 | 85 |
| Gabapentin | Gabapentin | 423 | 65 |
| Potassium Chloride | Potassium Chloride | 374 | 62 |
| Sertraline Hcl | Sertraline Hcl | 361 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 339 | 62 |
| Tamsulosin Hcl | Tamsulosin Hcl | 333 | 59 |
| Trazodone Hcl | Trazodone Hcl | 282 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 270 | 60 |
| Lisinopril | Lisinopril | 258 | 48 |
| Duloxetine Hcl | Duloxetine Hcl | 250 | 46 |
| Metformin Hcl | Metformin Hcl | 249 | 43 |
| Donepezil Hcl | Donepezil Hcl | 248 | 40 |
| Quetiapine Fumarate | Quetiapine Fumarate | 246 | 39 |
| Losartan Potassium | Losartan Potassium | 203 | 35 |
| Bumetanide | Bumetanide | 188 | 38 |
| Famotidine | Famotidine | 188 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 179 | 28 |
| Buspirone Hcl | Buspirone Hcl | 177 | 30 |
| Omeprazole | Omeprazole | 174 | 49 |
| Fluoxetine Hcl | Fluoxetine Hcl | 165 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 151 | 25 |
| Spironolactone | Spironolactone | 144 | 29 |
| Jardiance | Empagliflozin | 136 | 11 |
| Memantine Hcl | Memantine Hcl | 136 | 24 |
| Finasteride | Finasteride | 134 | 21 |
| Levetiracetam | Levetiracetam | 130 | 23 |
| Risperidone | Risperidone | 125 | 22 |
| Mirtazapine | Mirtazapine | 122 | 33 |
| Myrbetriq | Mirabegron | 121 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 115 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 111 | 19 |
| Divalproex Sodium | Divalproex Sodium | 103 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 102 | 16 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 100 | 20 |
| Latanoprost | Latanoprost | 100 | 22 |
| Allopurinol | Allopurinol | 98 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 96 | 14 |
| Topiramate | Topiramate | 93 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 92 | 22 |
| Aripiprazole | Aripiprazole | 91 | 17 |
| Novolog | Insulin Aspart | 90 | 15 |
| Baclofen | Baclofen | 88 | 16 |
| Midodrine Hcl | Midodrine Hcl | 87 | 23 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 86 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 80 | suppressed |
| Glipizide | Glipizide | 79 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 77 | 14 |
| Carvedilol | Carvedilol | 70 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 69 | 25 |
| Prednisone | Prednisone | 68 | 20 |
| Alendronate Sodium | Alendronate Sodium | 67 | suppressed |
| Simvastatin | Simvastatin | 65 | 16 |
| Budesonide | Budesonide | 62 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 61 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | suppressed |
| Lorazepam | Lorazepam | 60 | suppressed |
| Xarelto | Rivaroxaban | 60 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 59 | suppressed |
| Bupropion Xl | Bupropion Hcl | 56 | 11 |
| Digoxin | Digoxin | 56 | suppressed |
| Entresto | Sacubitril/Valsartan | 55 | suppressed |
| Olanzapine | Olanzapine | 55 | 12 |
| Trulicity | Dulaglutide | 52 | suppressed |
| Januvia | Sitagliptin Phosphate | 51 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 50 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 49 | suppressed |
| Primidone | Primidone | 49 | suppressed |
| Linzess | Linaclotide | 47 | suppressed |
| Cephalexin | Cephalexin | 44 | 18 |
| Clozapine | Clozapine | 43 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 42 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 42 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 41 | 14 |
| Lamotrigine | Lamotrigine | 40 | suppressed |
| Metolazone | Metolazone | 40 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | suppressed |
| Glimepiride | Glimepiride | 39 | suppressed |
| Haloperidol | Haloperidol | 39 | suppressed |
| Savella | Milnacipran Hcl | 39 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 18 |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 36 | suppressed |
| Ozempic | Semaglutide | 36 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 35 | suppressed |
| Humalog | Insulin Lispro | 35 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 34 | suppressed |
| Brilinta | Ticagrelor | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 33 | suppressed |
| Invokana | Canagliflozin | 33 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Scopolamine | Scopolamine | 31 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Torsemide | Torsemide | 29 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 28 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 28 | suppressed |
| Rexulti | Brexpiprazole | 28 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 28 | suppressed |
| Vraylar | Cariprazine Hcl | 28 | suppressed |
| Carbamazepine | Carbamazepine | 27 | suppressed |
| Insulin Lispro | Insulin Lispro | 27 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 25 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 25 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 24 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 24 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 24 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 23 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 23 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 15 |
| Rhopressa | Netarsudil Mesylate | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 16 |
| Meloxicam | Meloxicam | 21 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Ketoconazole | Ketoconazole | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 14 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Ezetimibe | Ezetimibe | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Levemir | Insulin Detemir | 17 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 16 | suppressed |
| Cefdinir | Cefdinir | 16 | 11 |
| Cinacalcet Hcl | Cinacalcet Hcl | 16 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 16 | suppressed |
| Nyamyc | Nystatin | 16 | suppressed |
| Acetic Acid | Acetic Acid | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Azithromycin | Azithromycin | 13 | 13 |
| Bupropion Hcl | Bupropion Hcl | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Humalog Junior Kwikpen | Insulin Lispro | 13 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Anastrozole | Anastrozole | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Fluphenazine Decanoate | Fluphenazine Decanoate | 11 | suppressed |
| Levobunolol Hcl | Levobunolol Hcl | 11 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Perindopril Erbumine | Perindopril Erbumine | 11 | suppressed |
| Phenytoin | Phenytoin | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $495.55 · 4 records | Neurocrine BioSciences, Inc. | INGREZZA, NUPLAZID | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nuplazid play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ACADIA Pharmaceuticals Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error